Highlights of our tech platform & competitive edge
Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.
Enabling novel modes of action with favorable benefit-to-risk profiles
We are establishing a proprietary pipeline of differentiated therapeutics by targeting clinically validated pathways with multispecific molecules to create novel mechanisms of action designed to differentiate from standard of care by superior efficacy and favorable safety. Our most advanced program, ND021, exemplifies this strategy by blocking immune-suppressive PD-(L)1 signaling with best-in-class potency and simultaneously triggering 4-1BB-mediated T cell stimulation specifically in the tumor microenvironment. ND021 is currently being evaluated in a Phase 1/2 clinical study.
NM21-1480: A novel tri-specific antibody for oncology
Learn more about its unique mode-of-action
Learn more about its unique mode-of-action
×
Latest News
May 20, 2021
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
Numab Therapeutics AG today announced the closing of a CHF 100…
Numab Therapeutics AG today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.
January 13, 2021
Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option
Numab Therapeutics AG today announced the formation of a global…
Numab Therapeutics AG today announced the formation of a global co-development and regional licensing agreement with Kaken Pharmaceutical for the company’s novel multispecific anti-inflammatory drug candidate NM26-2198, which blocks three key pathways in the pathophysiology of atopic dermatitis. The alliance builds on a collaboration and option agreement established in 2017.
September 30, 2020
Numab Therapeutics Appoints Daniel Vasella as new Chairman of the Board
Numab Therapeutics AG announced today the appointment of Dr. med.…
Numab Therapeutics AG announced today the appointment of Dr. med. Daniel Vasella, former Chairman and Chief Executive Officer of Novartis AG, as the new and independent Chairman of the Board of Numab. Dr. Vasella succeeds Dr. Oliver Middendorp, founder and current Chief Business Officer, who remains on the Board of Directors as a regular member.
